Healthcare Services

Global Liposomal Doxorubicin Market Expected to Reach $1.77 Billion by 2030 with 5.9% CAGR

April 2, 2026April 15, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Liposomal Doxorubicin Market At The End Of The 2026–2030 Forecast Period?

The liposomal doxorubicin market has experienced substantial growth in recent years. It is projected to expand from $1.32 billion in 2025 to $1.41 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. Factors contributing to its historical growth include the limitations of conventional doxorubicin toxicity, the increasing global cancer incidence, the early adoption of liposomal drug delivery, the expansion of oncology treatment protocols, and the growing hospital-based chemotherapy administration.

The market for liposomal doxorubicin is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach a value of $1.77 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.9%. The projected growth during this period stems from several factors, including the increasing demand for safer cancer treatments, a greater emphasis on enhancing patient quality of life, wider availability of oncology therapies in developing markets, the expansion of liposomal drug development initiatives, and a rise in approvals for generic oncology medications. Key trends anticipated during the forecast period encompass a growing preference for targeted chemotherapy formulations, the increasing application of liposomal drugs to mitigate cardiotoxicity, a rise in their adoption for ovarian and breast cancer treatments, the proliferation of generic liposomal doxorubicin products, and an escalating need for better drug tolerability in oncology.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16464&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Liposomal Doxorubicin Market?

The growing occurrence of cancer is projected to stimulate expansion within the liposomal doxorubicin market moving forward. Cancer denotes a collection of diseases that can emerge in virtually any bodily organ or tissue when abnormal cells multiply without restraint, extend beyond their usual limits, and either metastasize to other organs or penetrate adjacent body areas. The increase in cancer diagnoses stems from elements such as an older demographic, shifts in lifestyle, exposure to environmental factors, and more advanced diagnostic methods. Liposomal doxorubicin finds application in cancer therapy to improve the targeting of drugs to tumors, lessen adverse effects, and enhance treatment efficacy. As an illustration, in January 2024, the American Cancer Society, a US-based nonprofit cancer advocacy organization, reported an uptick in cancer cases to 2,001,140, up from 1,958,310 in 2023, indicating a 2.19% rise. Consequently, the increasing prevalence of cancer is fueling the growth of the liposomal doxorubicin market.

What Segment Types Make Up The Liposomal Doxorubicin Market?

The liposomal doxorubicin market covered in this report is segmented –

1) By Product: Doxil Or Caelyx, Lipodox, Myocet, Other Products

2) By Application: Breast Cancer, Kaposi Sarcoma, Other Applications

3) By End-Users: Hospitals, Homecare, Other End-Users

Subsegments:

1) By Doxil Or Caelyx: Different Dosage Strengths, Branded Versions, Generic Versions

2) By Lipodox: Different Dosage Strengths, Generic Versions

3) By Myocet: Different Dosage Strengths, Branded Versions

4) By Other Products: Newer Liposomal Formulations, Regional Brand Variants

What Trends Are Projected To Affect The Liposomal Doxorubicin Market?

Major companies operating in the liposomal doxorubicin market are concentrating on creating innovative liposomal injectable formulations, such as ready-to-use liposomal doxorubicin presentations, with the aim of enhancing the therapeutic index, decreasing systemic toxicity, and streamlining hospital administration when compared to traditional free-drug doxorubicin infusions. Liposomal doxorubicin represents a nanoparticle-encapsulated formulation where doxorubicin is contained within lipid bilayer vesicles, known as liposomes, which modifies pharmacokinetics and biodistribution. Its primary characteristics include an extended circulation time, selective tumor accumulation via the enhanced permeability and retention (EPR) effect, diminished cardiotoxicity, altered tissue exposure compared to non-encapsulated doxorubicin, and suitability for combination regimens. For instance, in July 2024, ForDoz Pharma Corp., a US–based specialty pharmaceutical company, obtained FDA approval for DOXOrubicin Hydrochloride Liposome Injection in ready-to-use 20 mg/10 mL and 50 mg/25 mL presentations. This approval covers ovarian cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma (with bortezomib), with the liposomal formulation facilitating sustained, tumor-targeted drug delivery and reduced peak-related toxicity, while its prefilled, standardized vials simplify preparation and dosing, providing enhanced tolerability, applicability for combination therapy, and an improved treatment workflow across various solid tumor and hematologic oncology settings.

Who Are The Key Players Driving Competition In The Liposomal Doxorubicin Market?

Major companies operating in the liposomal doxorubicin market are Johnson & Johnson, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Lupin Limited, Zydus Lifesciences Ltd., Accord Healthcare Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Mylan N.V., Apotex Inc., Natco Pharma Limited, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd., TTY Biopharm Company Limited, CSPC Pharmaceutical Group Limited, Luye Pharma Group Ltd., Qilu Pharmaceutical Co. Ltd., Chia Tai Tianqing Pharmaceutical Group, SRS Life Sciences

Read the full liposomal doxorubicin market report here:

https://www.thebusinessresearchcompany.com/report/liposomal-doxorubicin-global-market-report

Which Regions Are Projected To Dominate The Liposomal Doxorubicin Market In The Coming Years?

North America was the largest region in the liposomal doxorubicin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liposomal doxorubicin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Liposomal Doxorubicin Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16464&type=smp

Browse Through More Reports Similar to the Global Liposomal Doxorubicin Market 2026, By The Business Research Company

Doxorubicin Global Market Report

https://www.thebusinessresearchcompany.com/report/doxorubicin-global-market-report

Liposomal Drug Delivery Devices Global Market Report

https://www.thebusinessresearchcompany.com/report/liposomal-drug-delivery-devices-global-market-report

Lipid Global Market Report

https://www.thebusinessresearchcompany.com/report/lipid-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795